Compare Marqeta Inc (MQ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Revvity Inc — how do they compare? Marqeta Inc trades at $17.91 (market cap $1.82B), while Revvity Inc trades at $154.71 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 9.3× Marqeta Inc's market cap, and Revvity Inc pays a 0.18% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Revvity Inc for 12 Days on average.
| MQ | RVTY | |
|---|---|---|
Market Cap | $1.82B | $16.98B |
Volume | 1,126,466 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $20.32 | $157.36 |
52-Week Low | $15.04 | $82.26 |
Typical Hold Time | 44 Days | 12 Days |
Enterprise Value | $1.13B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $17.86, up 4.69% with a bullish technical outlook. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow generation in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives. However, valuation remains elevated with a P/E of 193.83 and EV/EBITDA of 54.37 despite modest profitability metrics.
MQ presents a mixed investment case with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and product innovation, though faces risks from contract renewals and competitive pressure. Analyst consensus at $11.38 suggests caution despite recent positive earnings revisions and institutional interest in the fintech sector.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
